In pancreatic and breast cancers, GSTM3 upregulation has been shown to significantly reduce reactive oxygen species (ROS) accumulation and simultaneously inhibit tumor cell glycolysis, altering the metabolic phenotype of the tumor cells. Here, GSTM3 is linked to neoplasm.